Navigation Links
U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
Date:1/12/2009

re than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey L.P. puts patients first through its development of innovative and affordable therapies. The Web sites for Dey L.P. include www.dey.com, www.accuneb.com, www.curosurfusa.com, www.cyanokit.com, www.duoneb.com, www.epipen.com and www.perforomist.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
2. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
3. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
4. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimers Patents and Patent Applications
5. Procter & Gamble Reaches Settlement on Patent Infringement Lawsuit
6. SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus
7. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
8. FreePatentsOnline Launches the CitePatents Program : Making it Easy for Bloggers and Journalists to Reference Patents, and Add Patent Search to Websites
9. HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral
10. Kidnapped senior needed IU-patented home security system
11. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... Metamora, Michigan (PRWEB) May 30, 2015 ... procedure to lighten or stop periods, without the ... This procedure can reduce or stop menstrual bleeding and ... the uterus (the part that causes the bleeding), with ... million women suffer from heavy menstrual bleeding. Many ...
(Date:5/30/2015)... Diego, CA (PRWEB) May 30, 2015 ... is the lack of local healthcare options available. Often, ... to adequate healthcare. For those in rural areas feeling ... simply without health insurance or tired of paying high ... new E-consults, connecting patients with licensed physicians via the ...
(Date:5/30/2015)... York (PRWEB) May 30, 2015 ... $100 million in punitive and compensatory damages to ... who suffered serious complications following implantation of the ... a verdict rendered on May 28th in Delaware ... in compensatory damages after the jury found that ...
(Date:5/30/2015)... EHO offers a suite of online applications ... the ability to manage their drug-spend for the lowest ... EHO has been able to compete with the big ... survive among the giants of the industry. Since EHO ... ago, it has simplified the way hospices can monitor ...
(Date:5/30/2015)... 30, 2015 Nicole Blodgett, Vice ... Income Associate (DIA) designation to further her expertise ... is designed for insurance advisors, health care professionals, ... knowledge and expertise associated with the risk and ... designation is only the latest accomplishment in Nicole's ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2
... Michigan Comprehensive Cancer Center have identified a potential new way ... cells in a tumor that fuel its growth and spread. ... by a type of cell derived from bone marrow, called ... marrow to the cancer and create a "niche" for the ...
... Controlling blood pressure is not only a medical challenge, ... required to strictly adhere to a treatment plan that ... the ideas of wellness and health are also powerful ... This is especially true in the African American ...
... 2011 - A recent study by Merikangas and colleagues ... Journal of the American Academy of Child and Adolescent ... that are affected with severely impairing mental disorders ever ... found that approximately one third of adolescents with any ...
... January 18, 2011 Heart disease is the leading cause ... States. But heart disease is more than just one disease; ... heart attack, high blood pressure, diabetes or other causes. In ... accumulation in heart cells. Obesity and high-fat diets are major ...
... the World Health Organisation (WHO), an estimated 322,000 deaths globally ... in many of these cases death could have been avoided ... major burn patients have insufficient skin left to graft on ... literally to be grown from the patient,s own skin cells. ...
... By Kathleen Doheny HealthDay Reporter , ... creams that promise "broad-spectrum" sun protection actually measure up, ... daytime moisturizers claiming to provide broad-spectrum protection from the ... reliable protection from harmful UV-A rays, which can penetrate ...
Cached Medicine News:Health News:U-M researchers find indirect path to attack breast cancer stem cells 2Health News:Storytelling may help control blood pressure in African-Americans 2Health News:Adolescents with severe mental disorders have never received treatment 2Health News:A different path to fat-related heart disease 2Health News:Nanotech medicine 2Health News:Nanotech medicine 3Health News:Nanotech medicine 4Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 2Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 3
(Date:5/29/2015)... and MENLO PARK, Calif. , ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... proven cancer therapies in new orphan drug indications, ... Association of Cancer Research (AACR) Advances in Brain ... its lead product candidate VAL-083 (dianhydrogalactitol) ...
(Date:5/29/2015)... 29, 2015 Amgen (NASDAQ: AMGN ... Phase 3, global, randomized, placebo-controlled trials evaluating AMG ... secondary hyperparathyroidism (SHPT) in patients with chronic kidney ... primary endpoint, demonstrating that a greater proportion of ... greater than 30 percent reduction in parathyroid hormone ...
(Date:5/28/2015)... -- Eli Lilly and Company (NYSE: LLY ) announced today ... for up to $1.6 billion aggregate principal amount of certain ... who tendered, and did not validly withdraw, their notes on ... time, on May 27, 2015 (the early tender date), ... to receive the total consideration. The total consideration for each ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... Amgen (Nasdaq: AMGN ) reported revenue unchanged ... $3,812 million for the third quarter of 2009. ... the third quarter of 2010 compared to $1,518 million for ... income was driven by unusually low research and development (R&D) ...
... 25 See video from Novartis: ... New Phase III data indicate that Menveo® (Meningococcal ... demonstrated robust immunogenicity in infants potentially offering protection ... 3. These data were presented during an oral ...
Cached Medicine Technology:Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 2Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 3Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 4Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 5Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 6Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 7Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 8Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 9Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 10Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 11Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 12Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 13Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 14Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 15
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
Medicine Products: